ABSTRACT
INTRODUCTION S
INCE ITS INTRODUCTION in late 1996, highly active antiretroviral therapy (HAART) has demonstrated its efficacy in reducing morbidity and mortality associated with HIV infection. [1] [2] [3] [4] [5] [6] [7] However, to date, HAART has been available only to less than 5% of those people who need it worldwide, and most of those accessing HAART are from high-income countries. 8 Indeed, even in those countries that enjoy sufficient resources, not everyone who fulfills the requirements for HIV treatment has equal access to it. 9, 10 There are reports of lack of treatment, inadequate care, and delays in commencing HAART among socially disadvantaged groups. 11 This fact may have special repercussions in Spain, where 50% of those people currently diagnosed with AIDS became HIV infected through sharing drug injection equipment 12 and account for the majority of those who need HIV treatment. Numerous studies have described how intravenous drug users (IDUs) have less access to HAART 9,11 because of their disadvantaged social situation, economic difficulties, and lack of family and social support. [13] [14] [15] [16] [17] [18] In Spain, antiretroviral therapy is available only through hospital prescription and this may act as a barrier for IDUs to access HAART. In fact, a lower and delayed population effectiveness of HAART among IDUs has been described in our setting. 13 Furthermore, even among those who have accessed the hospital system, IDUs often have higher physical and mental morbidity related to their drug addiction, 19, 20 which may also compromise their adherence to the treatment. 21, 22 All these facts may lead to lower uptake of treatment and poorer responses to HAART, which might have a bearing on IDU mortality. The aim of this study is to analyze differences in the uptake of HAART by categories of transmission, the virological response to therapy, and survival from AIDS diagnosis in a large nationwide multicenter hospital-based cohort.
MATERIALS AND METHODS
This cohort is the subject of a joint activity carried out by a recently created Research Network of Excellence (AIDS research network, RIS) funded by the Spanish Research Council, which incorporates basic scientists, immunologists, virologists, clinicians, epidemiologists, and statisticians. A total of 10 hospitals from 7 of the 17 Autonomous Communities in the country participate in this cohort. We defined a cohort of people infected with HIV, over 18 years of age, with at least 6 months of follow-up during the period of January 1, 1997 to December 31, 2003 at several centers in Spain (see the appendix). The patients were included at any time between January 1, 1997 and June 30, 2003 and analyses were concluded by December 31, 2003 . The total number of people included in the study amounted to 4643.
Each hospital provided a set of predefined variables in a convertible electronic format, as well as information on the methods used for laboratory determinations (CD4, viral load). The data required included sex, date of birth, most probable route of HIV infection, date of first confirmed HIV-positive result at the recruiting center, AIDS defining conditions (initial and during follow-up), and corresponding dates of diagnosis, antiretroviral treatments prescribed, and dates of initiation and completion, CD4 count, and viral load values in successive visits, as well as the dates of measurement, vital status, and cause and date of death.
The data were cross-checked with the National AIDS Register in September 2004, and the censoring date for these analyses was December 2003. Losses to follow-up were calculated by estimating the percentage of subjects still alive who had not been seen at the hospitals during the 12 months previous to December 2003 . Among the subjects with AIDS, 114 (10.7%) were lost to follow-up.
Statistical analyses
Descriptive analyses of demographic characteristics and clinical parameters for all transmission categories were carried out using frequency distributions or median and interquartile ranges (IQR) when appropriate.
Analyses of time to HAART initiation from study entry was assessed in the 3421 subjects who were HAART-naive at entry. Follow-up of patients not known to have started HAART by December 31, 2003 was based on the patients' last contact at the study center if it was before December 31, 2003 .
Inclusion criteria for the analyses of time to viral load suppression within 12 months from HAART initiation required a measurement of HIV-1 RNA viral load between 0 and 6 months before starting therapy higher than 500 copies/ml and at least one test for HIV RNA viral load measurement in the first 12 months after starting the therapy. A total of 1194 individuals were included in the analyses. The end-point used in the assessment of virological response to HAART was time to viral suppression, defined by the first HIV-1 RNA viral load measurement Ͻ500 copies/ml after the start of therapy. For this endpoint, patients were censored at the date of the last viral load if they did not achieve viral suppression at month 12 of therapy.
Analyses of survival from diagnosis of incident AIDS was assessed in 1061 subjects whose date of AIDS diagnosis was after January 1, 1997. Follow-up of people not known to be dead by December 31, 2003 was based on the patients' last contact at the study center if it was before December 31, 2003. We allowed for late entry of individuals with an AIDS diagnosis previous to study-entry, provided the AIDS diagnosis was after 1997. Late entry procedures aim to correct for the potential survivor bias introduced in the analysis by including subjects identified as having survived long enough.
Kaplan-Meier estimates of the cumulative probability of achieving each of the three outcomes of interest according to transmission category were calculated and compared using the log rank test. Cox proportional hazard models were used to assess the impact of transmission category on the three different outcomes adjusting for potential confounders and testing for effect modification. We used the likelihood ratio test to derive p values.
All models were stratified by center. Analyses were performed in Stata 8.0 (StataCorp, College Statin, TX) using robust methods to estimate confidence intervals.
RESULTS

Descriptive characteristics
A total of 4643 subjects were included in the study. Of these, 73% were men and the median age was [35] [36] [37] [38] [39] . Overall, 56.4% were injecting drug users, 22.6% heterosexuals, and 14.4% men who had sex with men (MSM). Among heterosexuals, 55.2% were women and among IDUs, 22.4% were women (Table 1) .
Twenty-one percent were diagnosed with AIDS prior to study entry and the incidence rate of AIDS during follow-up was 3.6 per 100 persons-year. Overall, 6.7% people died, the death rate being 1.7 per 100 persons-year (Table 1) .
Time to HAART initiation
Of 4643 patients, 26.3% had started HAART prior to study entry although this was less common among IDUs (25%). Of the 3421 HAART-naive subjects, 2613 started HAART during follow-up giving an overall rate of HAART initiation of 46.1 per 100 persons-year. Important differences by transmission category were observed; 39.4 per 100 persons-year among IDUs, 58.8 per 100 persons-year among heterosexuals, and 74.3 per 100 persons-year among MSM (Table 1) .
In univariate analyses, IDUs had a 25% lower probability of HAART initiation (HR 0.75 95% CI: 0.64-0.88) compared to MSM (HR 1.00) and heterosexuals (HR 0.95 95% CI: 0.84-1.09). Age was significantly associated with HAART initiation; for each 10 years of age, the probability of receiving treatment increased by 20% (HR 1.20 95% CI: 1.10-1.30) ( Table 2) Patients diagnosed with AIDS had a 74% higher probability of starting HAART than AIDS-free subjects (HR 1.74 95% CI: 1.56-1.95) and patients with HIV-1 RNA above 5 log 10 copies/ml had twice the probability of HAART initiation (HR 1.91 95% CI: 1.25-2.93) than those whose viral load was below 4 log 10 copies/ml (Table 2) .
A statistically significant interaction was detected between transmission category and having had previous antiretroviral treatment for HAART with either monotherapy and/or combination therapy (LRtest p Ͻ 0.05). Among antiretroviral naive patients, the uptake of HAART was clearly lower among IDUs (p Ͻ 0.001) (Fig. 1) , while among previously treated patients no differences in HAART initiation were observed by transmission group (Fig. 2) . In multivariate analyses, antiretroviral naive IDUs showed a 33% (HR 0.67 95% CI: 0.57-0.79) decreased probability of initiating HAART compared to MSM, adjusting for age, CD4 level, and previous AIDS diagnosis while no differences by transmission category were observed among subjects who had received prior antiretroviral treatment ( Table 3 ). The analysis was repeated stratifying by CD4 count level at study entry. Also among ARV naive patients whose 
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Time from HAART initiation to viral load suppression
The distribution of the number of viral load determinations of the patients included in these analyses did not show statistically significant differences between the transmission categories (median number of 3, range: 2-4). No differences were detected in the distribution of the times from initiation of HAART to the first VL measurement, for MSM 0.14 years (range: 0-0.28), for IDUs 0.13 (0-0.25), for heterosexuals 0.12 (range: 0-0.25), and for other 0.16 (range: 0.07-0.27); p ϭ 0.34. In univariate analyses, IDUs had a 15% lower probability (HR 0.85 95% CI: 0.75-0.97) to achieve virological suppression than MSM. No differences between MSM (HR 1.00) and heterosexuals (HR 1.08 95% CI: 0.93-1.25) were observed. Patients with AIDS diagnosis prior to HAART initiation were also less likely to achieve virological suppression (HR 0.79 95% CI: 0.66-0.86), as did patients who had received prior non-HAART antiretroviral therapy (HR 0.76 95% CI: 0.67-0.86). The higher the viral load at baseline, the lower the probability of suppression (Table 4) .
In multivariate analyses, the decreased probability of virological suppression observed in IDUs in univariate analyses was maintained (HR: 0.86 95% CI: 0.74-0.99), after adjusting for viral load level at HAART initiation, having a prior AIDS diagnosis (HR 0.81 95% CI: 0.69-0.94) and having received previous antiretroviral treatment (HR 0.71 95% CI: 0.57-0.89) ( Table 4) .
Survival from AIDS
Injecting drug users had a lower survival from AIDS diagnosis compared to MSM (log-rank test p ϭ 0.006) (Fig. 2) . In univariate analysis, the risk of death for IDUs was two and a half times higher than that of MSM (HR 2.44 95% CI: 1.06-5.60); no differences in survival were seen between MSM and heterosexuals (Table 5) . A higher survival was observed in women (HR 0.65 95% CI: 0.45-0.93), those who had received HAART (HR 0.41 95% CI: 0.28-0.60), and subjects with CD4 counts above 350 cells/l at AIDS diagnosis compared to below 200 cells/l (HR 0.51 95% CI: 0.30-0.88). Patients with a viral load of 4-5 log 10 copies/ml at AIDS diagnosis had a higher risk of death than those below 4 (HR: 2.39 95% CI: 1.44-3.97) ( Table 5) .
In multivariate analysis, the increased risk of death observed in IDUs compared to MSM in the univariate analyses was maintained (HR 2.51 95% CI: 1.03-6.1) ( Table 5) .
DISCUSSION
HIV-positive subjects infected through injecting drug use have a lower probability of receiving HAART, take longer to suppress their viral load once treatment is started, and show higher mortality once AIDS is diagnosed compared to patients infected through sexual transmission. One of the main determining factors for delaying the initiation of HAART is the lack of knowledge of the HIV status of the patient. 23, 24 However, in Spain, 70% of the new AIDS cases reported in 2004 who were unaware of their HIV status were infected by sexual contact, 12 while the majority of IDUs had been tested in the past. In fact, 78% of IDUs admitted for detoxification treatment in 2001 were aware of their HIV status. 25 However, early HIV diagnosis does not guarantee early treatment. In our study it was observed that even within the selected group of patients who had accessed the hospital system, IDUs still revealed a lower use of HAART. However, we have detected an interesting and statistically significant interaction: among those patients who had previously received antiretroviral non-HAART treatment, no differences by transmission category were found, whereas among antiretroviral naive subjects, the IDUs had a lower chance of receiving HAART. This may reflect a selection of the IDUs who had abandoned injecting drug use and who were, therefore, considered suitable candidates for HAART. 26 Unfortunately, no data on current drug injection were available. As expected, the probability of receiving HAART increased with clinical severity.
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The higher resistance to HAART initiation among injecting drug users has been attributed to their irregular adherence to the treatment and to the potential consequences resulting from poor compliance. A multicenter study performed in Italy reported a greater prevalence of nonadherence among IDUs, although the authors warned that given the high percentage of IDUs who completed therapy, drug use should not be used as a predictor of poor compliance. 27 Another factor that might explain the delay in HAART initiation among IDUs is the inexperience of some professionals in treating these patients, especially in contexts such as the one existing in Spain, where social services have not been developed in line with health care systems, and where it is essential that liaisons between care for HIV with drug addiction and the psychiatric services be improved. On some occasions the professionals prefer to delay the shift from non-HAART to HAART regimes until the patient achieves adherence or until he or she controls his or her addiction, 11, 26, 28 which compromises their prognosis. 29 It has been shown that once HAART is initiated, the response is similar among injecting drug users and noninjecting drug users. 2, 30 However, most authors have described worse virological responses 31 and, in general, a higher risk of progression to AIDS and death among IDUs. 13, 17, 31 We have also observed that IDUs show poorer viral suppression responses than other transmission categories after adjustment for viral load and level of CD4 at the onset of treatment, previous AIDS diagnosis, and previous treatment with antiretrovirals. 32 As well as attributing the worse response to treatment among IDUs to their poor adherence. 3, 13, 33 the additional difficulties encountered in adjusting the doses of antiretrovirals in this group of patients, which leads to suboptimum treatment, have been highlighted. 11, 15 This is particularly relevant if the patient is using drugs at the time of the treatment, 11, 34 which, in Spain, occurs in 10-20% of IDUs on HAART 35, 36 or in patients in a methadone program, 30 which is virtually a requirement for an injected drug user to be started on HAART. However, consideration might be given to reversing the present situation, and instead of demanding treat-
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FIG. 2. Time from AIDS to death by transmission category (n ϭ 1061).
A B ment of drug addiction as a condition for starting HAART, the initiation of HAART might be used as a tool to persuade IDUs to undergo treatment for drug addiction. As well as poorer compliance, the response to HAART might also be limited by a poorer immunological status secondary to the impact of opiates on the immune system. 37, 38 Furthermore, drug users may also have acute reactions to drugs, overdoses, recurrent infections, and liver function impairment resulting from HCV and HBV coinfections, 34, 39 which might result in higher levels of toxicity associated with HAART. For Dronda et al. being a drug user is an independent predictor of worse CD4 count recovery after initiating HAART, despite adequate virological suppression. 38 An important and positive finding of our study is the significant increase in survival after AIDS diagnosis observed in all the transmission categories, compared to the pre-HAART period. [3] [4] [5] [6] Nonetheless, injecting drug users still show the highest mortality rate, two and a half times higher than in MSM and heterosexuals, both in crude analysis and adjusted analysis. This may be attributed both to the lower uptake of HAART and poorer virological response described above and also to higher non-AIDS mortality, 40 this requiring further analyses. This higher mortality rate among IDUs has already been described both in Spain and in other countries, although there are no updated estimates and, at least in Spain, not for a large multicenter hospital-based cohort. 13, 14, 34 As expected, CD4 count and viral load measurements at AIDS were strong determinants of survival. 31, 34, 6, 41, 42 In our study, having received HAART was also associated with a clear survival advantage from AIDS diagnosis; however, given the design and analysis used, it is not possible to rule out a selection by indication bias, as those patients who are prescribed HAART are probably those with a greater a priori probability of survival. Additional causal modeling analyses are needed to separate these superimposed effects.
This study is the first outcome of a keenly motivated collaboration between the hospitals of 7 of the 17 Spanish Autonomous Communities, and is highly representative in geographical terms. The study suffers from external generalization, since evidently those people who do not access the hospital system are underrepresented; however, it may be assumed that their situation is even worse than that of the members of this cohort. An important limitation is the nonavailability of information on active drug use and participation in methadone programs, which limits some of the recommendations that might arise from this study. Losses to follow-up have been low, especially for the analysis from AIDS to death, where only 10.7% of subjects were missing. The cross-check with the National AIDS Registry maximized AIDS ascertainment.
In summary, of the patients who access the Spanish hospital network, IDUs have a lower uptake of HAART, have worse virological suppression, and, as a result, have a higher rate of mortality following AIDS diagnosis. This gross inequity is occurring in a country with free and universal access to health care and a developed hospital network. In 2004, from 5% to 10% of the 40 million people living with HIV/AIDS worldwide had been infected by sharing injection equipment. In Easter Europe, this is the main mechanism of HIV transmission. 43 We believe that there is a need to extend the programs in order to enhance access and adherence of drug users to HAART, tak- 
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